Article
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.
BMC cancer - 2 Oct 2020
Takeda Yuichiro, Naka Go, Yamaguchi Yoh, Hashimoto Masao, Suzuki Manabu, Izumi Shinyu, Sugiyama Haruhito
Abstract excerpt
BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), can be used as second-line treatment for lung cancer patients harboring the T790M substitution. Although osimertinib is more effective than the first-generation EGFR-TKIs used for first-line treatment, its efficacy with respect to long-term patient survival remains unclear even upon the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.